Open this photo in gallery AstraZeneca says its new antibody therapy reduced the risk of people developing any COVID-19 symptoms by 77 per cent in a late-stage trial. Dado Ruvic/ ReutersTrial data from AstraZeneca on Friday raised the prospect of a new treatment to prevent COVID-19 beyond vaccines, giving hope in particular for people who respond poorly to immunization shots. The British drugmaker said its new antibody therapy reduced the risk of people developing any COVID-19 symptoms by 77 per

The University of Oxford yesterday injected its new variant vaccine into people for the first time. Academics who created the original jab have updated their blueprint to target the variant first identified in South Africa, also known as B.1. 351 or Beta. This Variant of Concern emerged last year and is still in the UK at low levels.... It is also less susceptible to the vaccines than other strains, scientists believe.It became the prime candidate for the first “ variant vaccine ” and the Astra

LONDON( BLOOMBERG)-AstraZeneca Plc's Covid-19 antibody cocktail was found to be 77 per cent effective in preventing symptomatic Covid-19 in high-risk people in a key trial that could expand the range of drugs available to vulnerable groups. Results from AstraZeneca's study found no one in the trial who received the cocktail contracted severe Covid-19 or died in relation to the disease, the company said in a statement Friday( Aug 20). The trial of 5, 197 participants, which started in November, w

LONDON( REUTERS)-Covid-19 vaccines made by AstraZeneca and the Pfizer-BioNTech alliance remain broadly effective against Delta and Kappa variants of the Covid-19 causing virus, which were first identified in India, according to a scientific study, underpinning a continued push to deliver the shots. The study by Oxford University researchers, published in the journal Cell, investigated the ability of antibodies in the blood from people, who were vaccinated with the two-shot regimens, to neutralis

The group's treatment, known as AZD7442, is a combination of two antibodies and has been undergoing final clinical trials. AstraZeneca has announced it achieved a" statistically significant reduction in severe COVID-19 or death" in non-hospitalised patients with mild-to-moderate symptoms. The trial involved 903 participants and 90 percent of them were people at high risk of progression to severe COVID-19. Principal trial investigator Hugh Montgomery said:" With continued cases of serious COVID-1

Health Secretary Sajid Javid has said he is “ very confident ” there will be a booster programme, in a bid to avoid a winter lockdown. Evidence indicates the effectiveness of COVID-19 vaccines could wane over time, leading to calls for vulnerable Britons to receive a third dose. Other advanced economies, such as Israel and the United States, are already widely administering third doses in a bid to control the pandemic. However writing in the Daily Telegraph Pascal Soriot, chief executive of Astr

The Oxford jab has been snubbed around the EU after a smearing campaign against its side effects conducted across the whole continent since it was approved by the European Medicine Agency( EMA).... ín told the Czech radio station Radio？... urnál: “ There was simply no interest in the AstraZeneca vaccine....